Zymeworks (NYSE:ZYME) Coverage Initiated by Analysts at Lifesci Capital
Lifesci Capital initiated coverage on shares of Zymeworks (NYSE:ZYME – Free Report) in a research note published on Tuesday,Benzinga reports. The brokerage issued an outperform rating and a $30.00 target price on the stock. A number of other research analysts have also recently commented on ZYME. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” […]
